
Enanta Pharmaceuticals, Inc. (ENTA) Stock Ticker
ENTA right now
Market factors today
Unlock the full ENTA picture
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
ENTA stock facts
| Ticker symbol | ENTA |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $345.5M |
| CEO | Jay R. Luly |
| Employees | 120 |
| Headquarters | Watertown, MA, US |
| IPO date | 2013-03-21 |
| Website | www.enanta.com |
What you can see for ENTA on Tickr
Live ENTA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ENTA report.
Rankings
FAQ
What is the ticker symbol for Enanta Pharmaceuticals, Inc.?
The ticker symbol for Enanta Pharmaceuticals, Inc. is ENTA, listed on the NASDAQ Global Select.
What is ENTA?
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The…